All articles tagged with #drug supply chain
President Trump ordered a six-month stockpile of advanced pharmaceutical ingredients for critical drugs to reduce reliance on foreign supply chains, continuing efforts to bolster domestic production and national security in healthcare.
President Trump’s proposal to impose tariffs on pharmaceutical imports aims to address trade imbalances but risks disrupting the supply of essential medicines in the U.S., which heavily depends on China and India for raw materials. While bringing manufacturing back to the U.S. could enhance national security, the low margins and high costs make it challenging, and a comprehensive approach involving innovation, modernization, and large-scale initiatives is needed to reduce dependency and ensure drug supply stability.
Lawmakers are scrutinizing WuXi AppTec, a major Chinese company, over potential ties to the Chinese government, which has raised concerns about the U.S. supply chain for key drugs. The company is deeply involved in the development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V., and other illnesses, and its potential disconnection from U.S. pharmaceutical interests has rattled the biotech industry. Despite its significant role in the U.S. medicine chest, the Congressional spotlight on the company has led to discussions about potential national security threats and the impact of severing ties with the company.